Incretin-Based Therapies and Diabetic Retinopathy: Real-World Evidence in Older U.S. Adults
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Recent large trials yield conflicting results on the association between incretin-based therapies (IBTs) and diabetic retinopathy (DR). We examined whether IBTs increase DR risk compared with other antihyperglycemics. RESEARCH DESIGN AND METHODS: We implemented an active comparator, new-user cohort design using a nationwide 20% random sample of fee-for-service U.S. Medicare beneficiaries aged 65 years or older with Parts A, B, and D coverage between 2007 and 2015. We identified the following cohorts without prior treatment for retinopathy: dipeptidyl peptidase 4 inhibitors (DPP4i) versus sulfonylureas (SU), DPP4i versus thiazolidinediones (TZD), glucagon-like peptide-1 receptor agonists (GLP1RA) versus long-acting insulin (LAI), and GLP1RA versus TZD. Primary outcome was advanced diabetic retinopathy requiring treatment (ADRRT), defined as a procedure code for retinopathy treatment. Incident diabetic retinopathy (IDR), identified by a diagnosis code, was a secondary outcome. We estimated propensity scores to balance confounders and adjusted hazard ratios (95% CI) using weighted Cox proportional hazards models. RESULTS: We identified 213,652 eligible patients. During a median duration of 0.58 to 0.87 years across comparisons, with a rate from 6.0 to 12.8 per 1,000 person-years, IBTs were not associated with increased ADRRT or IDR risk. The adjusted hazard ratios (95% CI) for ADRRT were 0.91 (0.79–1.04) by comparing DPP4i to SU (n = 39,292 and 87,073); 0.91 (0.75–1.11), DPP4i to TZD (n = 51,410 and 22,231); 0.50 (0.39–0.65), GLP1RA to LAI (n = 9,561 and 82,849); and 0.75 (0.53–1.06), GLP1RA to TZD (n = 10,355 and 27,345). CONCLUSIONS: Our population-based cohort study of older U.S. adults with diabetes suggests that IBTs used for approximately 1 year do not increase the DR risk.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629
Self-citationSemaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900
Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes
Green, J. B., Bethel, M. A., Armstrong, P. W., Buse, J. B., Engel, S. S., Garg, J., Josse, R., Kaufman, K. D., Koglin, J., Korn, S., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501352 · Cited by 2,577 · cited 1×
“0 years) (8), whereas the Exenatide Study of Cardiovascular Event Lowering (EXSCEL) trial showed no increased retinopathy frequency in patients on GLP1RA exenatide (2.”
BackgroundSelf-citationLund, J. L., Richardson, D. B., & Stürmer, T. (2015) · Current Epidemiology Reports · doi:10.1007/s40471-015-0053-5 · Cited by 739 · cited 3×
“Using an active comparator study design helps to mitigate bias by only selecting individuals with an indication for initiating a secondline antidiabetes treatment, identifying individuals at a similar point in their disease management and ensuring only adverse events after drug initiation are evaluated (12).”
BackgroundSelf-citationEarly Worsening of Diabetic Retinopathy in the Diabetes Control and Complications Trial
(1998) · Archives of Ophthalmology · doi:10.1001/archopht.116.7.874 · Cited by 509
Pancreatic safety of incretin-based drugs–FDA and EMA assessment
Egan, A. G., Blind, E., Dunder, K., de Graeff, P. A., Hummer, B. T., Bourcier, T., & Rosebraugh, C. (2014) · New England Journal of Medicine · doi:10.1056/nejmp1314078 · Cited by 498
Incretin-Based Therapies for the Treatment of Type 2 Diabetes: Evaluation of the Risks and Benefits
Drucker, D. J., Sherman, S. I., Gorelick, F. S., Bergenstal, R. M., Sherwin, R. S., & Buse, J. B. (2010) · Diabetes Care · doi:10.2337/dc09-1499 · Cited by 316
Self-citationHernández, C., Bogdanov, P., Corraliza, L., García-Ramírez, M., Solà-Adell, C., Arranz, J. A., Arroba, A. I., Valverde, A. M., & Simó, R. (2016) · Diabetes · doi:10.2337/db15-0443 · Cited by 267 · cited 1×
“Topical administration of either GLP1RA (33) or DPP4i (34) prevents retinal neurodegeneration in mice.”
BackgroundCarls, G. S., Tuttle, E., Tan, R.-D., Huynh, J., Yee, J., Edelman, S. V., & Polonsky, W. H. (2017) · Diabetes Care · doi:10.2337/dc16-2725 · Cited by 153 · cited 3×
“Last, the real-world adherence and persistence to treatment is typically lower (14) than trials, and the median duration for treatment in our cohorts ranged from 0.”
BackgroundInfluentialArun, C. S., Pandit, R., & Taylor, R. (2004) · Diabetologia · doi:10.1007/s00125-004-1473-9 · Cited by 37
Research works printed but not linked: 26
- Gokhale, 2014, Dipeptidyl-peptidase-4 inhibitors and pancreatic cancer: a cohort study, Diabetes Obes Metab, 16, 1247, 10.1111/dom.12379 · DOI · Paper page
- Gilbert, 2015, Heart failure in diabetes: effects of anti-hyperglycaemic drug therapy, Lancet, 385, 2107, 10.1016/S0140-6736(14)61402-1 · DOI · Paper page
- Gokhale, 2017, No increased risk of cardiovascular events in older adults initiating dipeptidyl peptidase-4 inhibitors vs therapeutic alternatives, Diabetes Obes Metab, 19, 970, 10.1111/dom.12906 · DOI
- Holman, 2017, Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes, N Engl J Med, 377, 1228, 10.1056/NEJMoa1612917 · DOI · Paper page
- American Diabetes Association, 2017, Pharmacologic approaches to glycemic treatment. Sec. 8. In Standards of Medical Care in Diabetes—2017, Diabetes Care, 40, S64, 10.2337/dc17-S011 · DOI · Paper page
- Solomon, 2017, Diabetic retinopathy: a position statement by the American Diabetes Association, Diabetes Care, 40, 412, 10.2337/dc16-2641 · DOI · Paper page
- Parikh, 2017, Trends of anti-vascular endothelial growth factor use in ophthalmology among privately insured and Medicare Advantage patients, Ophthalmology, 124, 352, 10.1016/j.ophtha.2016.10.036 · DOI
- Varadhan, 2011, GLP-1 agonist treatment: implications for diabetic retinopathy screening, Diabetes Res Clin Pract, 94, e68, 10.1016/j.diabres.2011.08.017 · DOI
- Martinell, 2016, Prevalence and risk factors for diabetic retinopathy at diagnosis (DRAD) in patients recently diagnosed with type 2 diabetes (T2D) or latent autoimmune diabetes in the adult (LADA), J Diabetes Complications, 30, 1456, 10.1016/j.jdiacomp.2016.08.009 · DOI
- Sato, 2003, Marginal structural models as a tool for standardization, Epidemiology, 14, 680, 10.1097/01.EDE.0000081989.82616.7d · DOI · Paper page
- Cole, 2004, Adjusted survival curves with inverse probability weights, Comput Methods Programs Biomed, 75, 45, 10.1016/j.cmpb.2003.10.004 · DOI · Paper page
- Rubin, 2004, Multiple Imputation for Nonresponse in Surveys
- Silva, 2015, Telemedicine and eye examinations for diabetic retinopathy: a time to maximize real-world outcomes, JAMA Ophthalmol, 133, 525, 10.1001/jamaophthalmol.2015.0333 · DOI
- Makri, 2013, Drug-induced macular edema, Drugs, 73, 789, 10.1007/s40265-013-0055-x · DOI
- Nencini, 2008, Retinopathy induced by drugs and herbal medicines, Eur Rev Med Pharmacol Sci, 12, 293
- Stürmer, 2007, Adjustments for unmeasured confounders in pharmacoepidemiologic database studies using external information, Med Care, 45, S158, 10.1097/MLR.0b013e318070c045 · DOI
- Stürmer, 2013, Cancer incidence among those initiating insulin therapy with glargine versus human NPH insulin, Diabetes Care, 36, 3517, 10.2337/dc13-0263 · DOI
- Wahl, 2016, Erratum to: Assessment of predictive performance in incomplete data by combining internal validation and multiple imputation, BMC Med Res Methodol, 16, 170, 10.1186/s12874-016-0271-7 · DOI
- Sterne, 2009, Multiple imputation for missing data in epidemiological and clinical research: potential and pitfalls, BMJ, 338, b2393, 10.1136/bmj.b2393 · DOI · Paper page
- Simó, 2017, GLP-1R as a target for the treatment of diabetic retinopathy: friend or foe?, Diabetes, 66, 1453, 10.2337/db16-1364 · DOI · Paper page
- Hernández, 2017, Topical administration of DPP-IV inhibitors prevents retinal neurodegeneration in experimental diabetes, Diabetologia, 60, 2285, 10.1007/s00125-017-4388-y · DOI
- The Kroc Collaborative Study Group, 1988, Diabetic retinopathy after two years of intensified insulin treatment. Follow-up of the Kroc Collaborative Study, JAMA, 260, 37, 10.1001/jama.1988.03410010045032 · DOI · Paper page
- Lauritzen, 1985, Two-year experience with continuous subcutaneous insulin infusion in relation to retinopathy and neuropathy, Diabetes, 34, 74, 10.2337/diab.34.3.S74 · DOI · Paper page
- Idris, 2012, Association between thiazolidinedione treatment and risk of macular edema among patients with type 2 diabetes, Arch Intern Med, 172, 1005, 10.1001/archinternmed.2012.1938 · DOI · Paper page
- Gower, 2018, Lack of longitudinal association between thiazolidinediones and incidence and progression of diabetic eye disease: the ACCORD Eye study, Am J Ophthalmol, 187, 138, 10.1016/j.ajo.2017.12.007 · DOI
- Chubak, 2012, Tradeoffs between accuracy measures for electronic health care data algorithms, J Clin Epidemiol, 65, 343, 10.1016/j.jclinepi.2011.09.002 · DOI · Paper page
Cited by
Gaborit, B., Julla, J.-B., Besbes, S., Proust, M., Vincentelli, C., Alos, B., Ancel, P., Alzaid, F., Garcia, R., Mailly, P., et al. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgz069 · Cited by 95
Lin, D. S., Lo, H., Huang, K., Lin, T., Lee, J., & Lin, L. (2024) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15788 · Cited by 16
“In the present study, the differential effects of GLP1RA and SGLT2i on DR events were evident only in those with pre-existing DR.”
InfluentialYen, F.-S., Wei, J. C.-C., Shih, Y.-H., Hung, Y.-T., Hsu, T.-J., Hsu, C.-C., & Hwu, C.-M. (2024) · Diabetes & Metabolic Syndrome: Clinical Research & Reviews · doi:10.1016/j.dsx.2024.103099 · Cited by 13
Anatriello, A., Liguori, V., Cagnotta, C., Pentella, C., Scavone, C., Capuano, A., & Rinaldi, B. (2026) · Frontiers in pharmacology · doi:10.3389/fphar.2026.1808359 · Cited by 3
Metadata
- Authors
- Wang, T., Hong, J.-L., Gower, E. W., Pate, V., Garg, S., Buse, J. B., & Stürmer, T.
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2018-07-16
- Volume
- 41
- Issue
- 9
- Pages
- 1998-2009
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2883137353
- Cited by
- 52
- References
- 10
- FWCI
- 4.26
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.